Anifrolumab, a relatively new monoclonal antigen, is sparking considerable interest within the healthcare community as a potential option for various inflammatory ailments. This innovative medication targets the IFN https://socialrus.com/story24726633/anifrolumab-a-novel-approach-for-immune-mediated-diseases